Literature DB >> 21935647

Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

Moritz Treiber1, Gunther Wernsdorfer, Ursula Wiedermann, Kanungnit Congpuong, Jeeraphat Sirichaisinthop, Walther H Wernsdorfer.   

Abstract

Excepting tropical Africa, where Plasmodium falciparum prevails, Plasmodium vivax is the most frequent cause of malaria in Asia and Latin America. First reliable reports of chloroquine resistance came in 1989 from the area of the distribution of the Chesson-strain of P. vivax. Since then, reports also came from other areas of the world. This study had the objective of measuring the sensitivity of P.vivax to chloroquine and potential alternative compounds in western Thailand. The study was performed in 2008 in Mae Sot, Tak Province, and followed the method of Tasanor. The IC(50) and IC(90) values for chloroquine were 167 nM and 5445 nM, those for mefloquine were 139 nM and 5282 nM, those for artemisinin were 32 nM and 466 nM, and those for atovaquone 30 nM and 650 nM. The values for chloroquine indicate the existing or imminent occurrence of specific resistance. High prevalence of mefloquine resistance precludes its alternative use. However, atovaquone, in combination with proguanil, may be a possible alternative.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21935647     DOI: 10.1007/s00508-011-0044-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  29 in total

1.  Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region.

Authors:  G Alecrim M das; W Alecrim; V Macêdo
Journal:  Rev Soc Bras Med Trop       Date:  1999 Jan-Feb       Impact factor: 1.581

2.  Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.

Authors:  J A Simpson; R Price; F ter Kuile; P Teja-Isavatharm; F Nosten; T Chongsuphajaisiddhi; S Looareesuwan; L Aarons; N J White
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

3.  Studies on the characterization of plasmodium vivax strains from Central America.

Authors:  P G Contacos; W E Collins; G M Jeffery; W A Krotoski; W A Howard
Journal:  Am J Trop Med Hyg       Date:  1972-09       Impact factor: 2.345

4.  Plasmodium vivax clinically resistant to chloroquine in Colombia.

Authors:  J Soto; J Toledo; P Gutierrez; M Luzz; N Llinas; N Cedeño; M Dunne; J Berman
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

5.  Susceptibility to chloroquine, mefloquine and artemisinin of Plasmodium vivax in northwestern Thailand.

Authors:  Birgit Woitsch; Gunther Wernsdorfer; Kanungnit Congpuong; Chaiporn Rojanawatsirivet; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

6.  Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua.

Authors:  Mazie J Barcus; Hasan Basri; Helena Picarima; C Manyakori; Iqbal Elyazar; Michael J Bangs; Jason D Maguire; J Kevin Baird
Journal:  Am J Trop Med Hyg       Date:  2007-11       Impact factor: 2.345

Review 7.  The global distribution and population at risk of malaria: past, present, and future.

Authors:  Simon I Hay; Carlos A Guerra; Andrew J Tatem; Abdisalan M Noor; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

8.  Chloroquine-resistant Plasmodium vivax malaria in Peru.

Authors:  Trenton K Ruebush; Jorge Zegarra; Javier Cairo; Ellen M Andersen; Michael Green; Dylan R Pillai; Wilmer Marquiño; María Huilca; Ernesto Arévalo; Coralith Garcia; Lely Solary; Kevin C Kain
Journal:  Am J Trop Med Hyg       Date:  2003-11       Impact factor: 2.345

9.  Plasmodium vivax malaria.

Authors:  Dhanpat K Kochar; Vishal Saxena; Narvachan Singh; Sanjay K Kochar; S Vijay Kumar; Ashis Das
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

10.  Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.

Authors:  Hiwot Teka; Beyene Petros; Lawrence Yamuah; Gezahegn Tesfaye; Ibrahim Elhassan; Simon Muchohi; Gilbert Kokwaro; Abraham Aseffa; Howard Engers
Journal:  Malar J       Date:  2008-10-29       Impact factor: 2.979

View more
  6 in total

1.  In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.

Authors:  Diana Fernández; César Segura; Margarita Arboleda; Giovanny Garavito; Silvia Blair; Adriana Pabón
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

2.  The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.

Authors:  Michael Delves; David Plouffe; Christian Scheurer; Stephan Meister; Sergio Wittlin; Elizabeth A Winzeler; Robert E Sinden; Didier Leroy
Journal:  PLoS Med       Date:  2012-02-21       Impact factor: 11.069

Review 3.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

4.  Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.

Authors:  Henry M Staines; Rebekah Burrow; Beatrix Huei-Yi Teo; Irina Chis Ster; Peter G Kremsner; Sanjeev Krishna
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

5.  Plasmodium knowlesi as a model system for characterising Plasmodium vivax drug resistance candidate genes.

Authors:  Lisa H Verzier; Rachael Coyle; Shivani Singh; Theo Sanderson; Julian C Rayner
Journal:  PLoS Negl Trop Dis       Date:  2019-06-03

6.  A Mitochondria-Penetrating Peptide Exerts Potent Anti-Plasmodium Activity and Localizes at Parasites' Mitochondria.

Authors:  Sangdao Somsri; Mathirut Mungthin; Natthaporn Klubthawee; Poom Adisakwattana; Warunee Hanpithakpong; Ratchaneewan Aunpad
Journal:  Antibiotics (Basel)       Date:  2021-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.